Role of coronary microvascular dysfunction in takotsubo syndrome bit.ly/4mozijl

Natural history of asymptomatic moderate or severe aortic regurgitation: a systematic review and meta-analysis Please read the article and enjoy an in-depth interview between @jhfrudd and the first author, Dr Jwan Naser from The Mayo Clinic in Rochester, Minnesota, USA Paper: bit.ly/4tVHsCM Interview: bit.ly/3R1Tr38

The next frontier for prevention of heart and vascular disease isn't targeting lipids. It's about blocking inflammation. These are some of the ongoing clinical trials @NatureMedicine nature.com/articles/d41591-0…

NEW ASE Recommendations for the Intraprocedural Imaging for M-TEER bit.ly/ASE_M-TEER @SLittleMD @ASE360 @JournalASEcho @ACCinTouch @SCAI @purviparwani @iamritu

Today @OpenAI introduced ChatGPT for Clinicians, provided free for credentialed HCPs, and HealthBench Professional for benchmarking LLM medical task performance (Figure) openai.com/index/making-chat… cdn.openai.com/dd128428-0184…

Finally, a sham-controlled CTO PCI trial—and it delivers. ORBITA-CTO: small (n=50), but rigor where it matters—blinding, placebo control, symptom-level data. CTO PCI improves angina beyond placebo, with a clear reduction in episodes and more angina-free days. Not prognosis, not hard endpoints, but real symptom benefit—properly measured. #acc26 jacc.org/doi/10.1016/j.jacc.…

Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION–STEMI trial academic.oup.com/eurheartj/a…

Optimization of Distal Radial Access Into Clinical Routine Practice Through Ultrasound Guidance: A Review and Technical Guide imrpress.com/journal/RCM/27/…

#Delirium is not “just confusion”, it is a major prognostic event in CV medicine. In our State-of-the-Art Review in #EHJ, we synthesize current evidence on mechanisms, prevention, and management across the CV continuum. 🧠🫀 acortar.link/PfFZLf @CekajEndrit et al👏👏

Clopidogrel outperformed aspirin in preventing cardiovascular events in patients with coronary artery disease (CAD), showing superior efficacy across both genders, in PANTHER-2 trial. ahajrnls.org/4tLXHTo

🧵 1/ First ever AHA/ACC/multi-society guidelines re: diagnosis & management of acute PE released today! 2 year effort with 38 authors from 10 specialties. Link attached & summary in this thread: jacc.org/doi/10.1016/j.jacc.…

The SCAPIS study published in JAMA ~25,000 🇸🇪 participants, ~8 years follow-up. Adding coronary CT angiography #CCTA plaque information improved event prediction beyond clinical risk and calcium score. This is the first study showing the added value of CCTA on top of the calcium score for risk prediction. 🎯 What to look for: lipidic soft (non-calcified) plaque. 👀 Practical takeaway: Consider a CT angiography for risk stratification on top of the calcium score. Link: jamanetwork.com/journals/jam… 🎥 Posting my avatar summarizing the study.

With 561 references, this article—published in Nature Reviews Cardiology—is among the most comprehensive reviews of the pathophysiology, biomarkers, and therapeutic strategies addressing residual risk in coronary artery disease. Read more at bit.ly/4q3Fain

Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure. Read the results of the OPTION–STEMI trial in #EHJ 👉 ow.ly/MiAx50XTiiv @RoccoMontone @ehj_ed #heartfailure

STEMI and cardiogenic shock. A time course analysis of the use of microaxial flow pump (mAFP) and clinical outcomes from the DanGer Shock trial @CardResearchOUH @cardiac_group @RigsHeart ahajrnls.org/4jIuoN0

The risk of high lipoprotein A [Lp(a)] in nearly 28,000 healthy women followed for 30 years. Fortunately, after waiting for decades, we will have drugs vs Lp(a) soon to reduce this risk jamanetwork.com/journals/jam…

Plaque rupture with thrombosis drives ACS, and thin-cap fibroatheroma is the archetypal high-risk plaque. There are consistent features of vulnerability across imaging modalities (large plaque burden, small MLA, TCFA, high LCBI, positive remodelling, etc.), with risk increasing when multiple features coexist. Yet absolute event rates remain low, consistent with pathology data showing most plaque ruptures are clinically silent. So should we prophylactically stent high-risk plaques? According to this Viewpoint, completed trials (PROSPECT ABSORB, PREVENT) suggest no durable reduction in death or MI versus optimal medical therapy—benefits are limited to fewer revascularisations, at the cost of many unnecessary PCIs. With modern medical therapy, a wait-and-see strategy appears safe, avoiding most interventions without adverse consequences. For now, data favor surveillance and aggressive medical therapy over preventive PCI. READ THE VIEWPOINT: eurointervention.pcronline.c…

Bicuspid is no longer a niche. In this SOTA, @didier_tchetche et al walk through TAVI in BAV: phenotypes, CT sizing (BAVARD, circle, CASPER), procedural tricks, long-term concerns and the need for TAVI vs SAVR RCTs. Don't miss it 👉eurointervention.pcronline.c… #TAVI #cardiotwitter #CardioX #CardioEd @YWillemen @Vinscesario

We should read this, then read it again, then use the info in our shared decision making conversation

The natural history of patients with medically managed CCS is not as benign as we think. Our analysis of reconstructed individual patient's data from 29 trials and 53,000 pts shows AMI rates of 12.5% at 5 years and 8.6% mortality rate. Outcomes will be much worse in non RCT real-world populations where risk factor control less optimal and multimorbidity more prevalent. work led by @Nicholaswschew and team ➡️ link.springer.com/article/10…